Bristol-Myers Squibb Company (BMY) is listed on NYSE in Pharmaceutical Stocks. It is $66.58, -0.55%, with a $136.0B market cap. RSI is 60.7, near overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 60.7 Near Overbought
Market Cap $136.0B
Volume 4.3M
Fundamentals — 10-Q Q2 2026
Revenue $24.5B
Net Income $6.0B
EPS $2.93
Gross Margin 70.8%
Net Margin 24.5%
Debt / Equity 1.9x
P/E Ratio 22.7x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Holzer Phil M | SVP and Controller | Sell | 500 | $67.50 | $33,750 | 2026 Aug 25 |
| Elkins David V | EVP, Chief Financial Officer | Sell | 56,000 | $47.33 | $2.7M | 2025 Sep 2 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sell | 378 | $44.23 | $16,719 | 2025 Aug 2 |
| Hickey Benjamin | President, RayzeBio Org. | Sell | 97 | $38.01 | $3,702 | 2025 May 9 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,250 | $47.58 | $202,215 | 2025 Apr 25 |
| Boerner Christopher S. | Chief Executive Officer | Buy | 2,000 | $55.05 | $110,100 | 2025 Feb 20 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,823 | $54.84 | $100,000 | 2025 Feb 14 |
| Holzer Phil M | SVP and Controller | Sell | 700 | $55.62 | $38,934 | 2024 Nov 4 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,830 | $54.68 | $100,064 | 2024 Nov 1 |
| Boerner Christopher S. | Chief Executive Officer | Buy | 2,000 | $49.78 | $99,560 | 2023 Dec 5 |
| Boerner Christopher S. | Chief Executive Officer | Buy | 3,071 | $48.86 | $150,049 | 2023 Nov 28 |
| Samuels Theodore R. II | Director | Buy | 8,500 | $49.81 | $423,385 | 2023 Nov 20 |
| Powell Ann | EVP, Chief Human Resources | Sell | 17,986 | $61.25 | $1.1M | 2023 Aug 24 |
| Plenge Robert M | EVP, Chief Research Officer | Sell | 732 | $61.14 | $44,754 | 2023 Aug 3 |
| Vessey Rupert | EVP & President, Research | Sell | 50,385 | $67.06 | $3.4M | 2023 May 3 |
| Powell Ann | EVP, Chief Human Resources | Sell | 11,183 | $74.69 | $835,258 | 2023 Feb 6 |
| Caforio Giovanni | Board Chair and CEO | Sell | 240,000 | $74.65 | $17.9M | 2023 Feb 6 |
| Powell Ann | EVP, Chief Human Resources | Sell | 16,250 | $80.45 | $1.3M | 2022 Nov 9 |
| Vessey Rupert | EVP, Research & Early Dev. | Sell | 45,910 | $78.88 | $3.6M | 2022 Nov 7 |
| Caforio Giovanni | Board Chair and CEO | Sell | 25,000 | $69.71 | $1.7M | 2022 Sep 20 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $77.31 | 53.6 | $31.9B |
| | $236.99 | 45.2 | $31.7B |
| | $162.66 | 48.4 | -- |
| | $515.52 | 46.7 | $22.1B |
Take BMY further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put BMY in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Bristol-Myers Squibb Company next reports.
Set alerts on BMY
Get notified when Bristol-Myers Squibb Company hits your price targets or technical conditions are met.
Get Started Free